NCT03272009View on ClinicalTrials.gov

Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 21, 2017

Primary Completion Date

July 30, 2018

Study Completion Date

July 30, 2018

Conditions
Hepatitis B, Chronic
Interventions
DRUG

EYP001a

Capsules administered orally. Number of morning and evening capsules depending on treatment arm

DRUG

Placebo

Placebo capsules for oral administration, identical in appearance to the EYP001a capsules

DRUG

Entecavir

Tablets administered orally

DRUG

peg-interferon alfa-2a

Ready-to-Use pre-filled syringes for subcutaneous injection

Trial Locations (9)

2031

Scientia Clinical Research Limited, Sydney

6009

Linear Clinical Research Limited, Perth

10330

King Chulalongkorn Memorial Hospital, Bangkok

10400

Hospital for Tropical Diseases, Bangkok

Unknown

Academic Medical Centre (AMC), Amsterdam

Erasmus MC, Rotterdam

Klinika Chorób Zakaźnych I Hepatologii UMB, Bialystok

HepID, Lublin

25-317

Klinika Chorób Zakaźnych, Kielce

Sponsors

Lead Sponsor

Enyo Pharma
All Listed Sponsors
collaborator

CPR Pharma Services Pty Ltd, Australia

INDUSTRY

lead

Enyo Pharma

INDUSTRY